 This study uses Solanezumab and Gautenerumab.Gautenerumab, the first fully human MAB that preferentially interacts with oligomerized Aβ plaques in the brain, caused significant reduction in Aβ concentration in Phase I clinical trials, preventing plaque formation and concentration without altering plasma concentration of the brain.Phase II and III clinical trials are currently being conducted.